Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in High-Risk Corneal Transplant Survival
NCT01996826Phase 2Completed
- Start
- Apr 2014
- Primary completion
- Apr 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in corneal graft rejection (CGR), corneal neovascularization (CNV). Started Apr 2014; status: completed.
02
Drugs
bevacizumab
03
Conditions
corneal graft rejection (CGR)corneal neovascularization (CNV)
Beyond the preview
Go deeper on NCT01996826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01996826.